Recent developments in the epidemiology, diagnosis, and treatment of Fasciola infection

Camille M. Webb, Miguel Cabada

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: This review aims at describing the latest research in Fasciola epidemiology, diagnosis, treatment, and control in endemic countries. RECENT FINDINGS: The geographic distribution and range of reservoirs for Fasciola hepatica continues to expand. The impact of fascioliasis goes beyond human disease to affect food security and income in developed and developing countries. Promising serologic and molecular methods to diagnose fascioliasis have been described, but are not widely available. Triclabendazole remains the only highly active medication to treat human and livestock infected with juvenile and adult forms of Fasciola spp. Efforts to control fascioliasis may be hindered by the emergence of resistance to triclabendazole among livestock and subsequently in humans. SUMMARY: Increased awareness and surveillance are likely to uncover the real distribution and burden of fascioliasis in human. Research into new drugs or adjuvants to tackle the emerging resistance to triclabendazole is imperative to treat and control Fasciola infection.

Original languageEnglish (US)
Pages (from-to)409-414
Number of pages6
JournalCurrent opinion in infectious diseases
Volume31
Issue number5
DOIs
StatePublished - Oct 1 2018

Fingerprint

triclabendazole
Fasciola
Fascioliasis
Epidemiology
Livestock
Infection
Fasciola hepatica
Food Supply
Infection Control
Research
Developed Countries
Developing Countries
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Recent developments in the epidemiology, diagnosis, and treatment of Fasciola infection. / Webb, Camille M.; Cabada, Miguel.

In: Current opinion in infectious diseases, Vol. 31, No. 5, 01.10.2018, p. 409-414.

Research output: Contribution to journalArticle

@article{62711576cfa3409d80c4de6146913082,
title = "Recent developments in the epidemiology, diagnosis, and treatment of Fasciola infection",
abstract = "PURPOSE OF REVIEW: This review aims at describing the latest research in Fasciola epidemiology, diagnosis, treatment, and control in endemic countries. RECENT FINDINGS: The geographic distribution and range of reservoirs for Fasciola hepatica continues to expand. The impact of fascioliasis goes beyond human disease to affect food security and income in developed and developing countries. Promising serologic and molecular methods to diagnose fascioliasis have been described, but are not widely available. Triclabendazole remains the only highly active medication to treat human and livestock infected with juvenile and adult forms of Fasciola spp. Efforts to control fascioliasis may be hindered by the emergence of resistance to triclabendazole among livestock and subsequently in humans. SUMMARY: Increased awareness and surveillance are likely to uncover the real distribution and burden of fascioliasis in human. Research into new drugs or adjuvants to tackle the emerging resistance to triclabendazole is imperative to treat and control Fasciola infection.",
author = "Webb, {Camille M.} and Miguel Cabada",
year = "2018",
month = "10",
day = "1",
doi = "10.1097/QCO.0000000000000482",
language = "English (US)",
volume = "31",
pages = "409--414",
journal = "Current Opinion in Infectious Diseases",
issn = "0951-7375",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Recent developments in the epidemiology, diagnosis, and treatment of Fasciola infection

AU - Webb, Camille M.

AU - Cabada, Miguel

PY - 2018/10/1

Y1 - 2018/10/1

N2 - PURPOSE OF REVIEW: This review aims at describing the latest research in Fasciola epidemiology, diagnosis, treatment, and control in endemic countries. RECENT FINDINGS: The geographic distribution and range of reservoirs for Fasciola hepatica continues to expand. The impact of fascioliasis goes beyond human disease to affect food security and income in developed and developing countries. Promising serologic and molecular methods to diagnose fascioliasis have been described, but are not widely available. Triclabendazole remains the only highly active medication to treat human and livestock infected with juvenile and adult forms of Fasciola spp. Efforts to control fascioliasis may be hindered by the emergence of resistance to triclabendazole among livestock and subsequently in humans. SUMMARY: Increased awareness and surveillance are likely to uncover the real distribution and burden of fascioliasis in human. Research into new drugs or adjuvants to tackle the emerging resistance to triclabendazole is imperative to treat and control Fasciola infection.

AB - PURPOSE OF REVIEW: This review aims at describing the latest research in Fasciola epidemiology, diagnosis, treatment, and control in endemic countries. RECENT FINDINGS: The geographic distribution and range of reservoirs for Fasciola hepatica continues to expand. The impact of fascioliasis goes beyond human disease to affect food security and income in developed and developing countries. Promising serologic and molecular methods to diagnose fascioliasis have been described, but are not widely available. Triclabendazole remains the only highly active medication to treat human and livestock infected with juvenile and adult forms of Fasciola spp. Efforts to control fascioliasis may be hindered by the emergence of resistance to triclabendazole among livestock and subsequently in humans. SUMMARY: Increased awareness and surveillance are likely to uncover the real distribution and burden of fascioliasis in human. Research into new drugs or adjuvants to tackle the emerging resistance to triclabendazole is imperative to treat and control Fasciola infection.

UR - http://www.scopus.com/inward/record.url?scp=85063686873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063686873&partnerID=8YFLogxK

U2 - 10.1097/QCO.0000000000000482

DO - 10.1097/QCO.0000000000000482

M3 - Article

C2 - 30113327

AN - SCOPUS:85063686873

VL - 31

SP - 409

EP - 414

JO - Current Opinion in Infectious Diseases

JF - Current Opinion in Infectious Diseases

SN - 0951-7375

IS - 5

ER -